FibroBiologics receives Nasdaq delisting notice for bid price non-compliance

FibroBiologics, Inc.

Nasdaq Staff Determination on July 22, 2026: bid price below $1.00 for 30 consecutive business days (June 8–July 21, 2026).
Company ineligible for 180-day cure period due to reverse stock split within prior year (Listing Rule 5810(c)(3)(A)(iv)).
Delisting scheduled for July 31, 2026 unless appeal requested by July 29, 2026; company intends to request hearing.
At hearing, company will present plan to regain compliance; no assurance of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.